Clinical Trial to Evaluate the Efficacy and Safety of Sarpogrelate SR in Patients With Chronic Artery Occlusive Disease
- Conditions
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Yuhan Corporation
- Target Recruit Count
- 148
- Registration Number
- NCT06046196
- Locations
- 🇰🇷
GangNeung Asan Hospital, Gangneung-si, Gangwon-do, Korea, Republic of
🇰🇷Inje University Ilsan Paik Hospital, Goyang-si, Gyeonggi-do, Korea, Republic of
🇰🇷Dong-A University Hospital, Busan, Korea, Republic of
Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients with Essential Hypertension
- Conditions
- Interventions
- First Posted Date
- 2023-09-18
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Yuhan Corporation
- Target Recruit Count
- 250
- Registration Number
- NCT06041529
- Locations
- 🇰🇷
Pusan National University Yangsan Hospital, Busan, Korea, Republic of
🇰🇷Wonju Severance Christian Hospital, Gangwon-do, Korea, Republic of
🇰🇷Gwangju Veterans Hospital, Gwangju, Korea, Republic of
A Single Dose, Phase 1 Study of YH35324 in Patients with Various Allergic Diseases
- Conditions
- Interventions
- First Posted Date
- 2023-07-27
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Yuhan Corporation
- Target Recruit Count
- 36
- Registration Number
- NCT05960708
- Locations
- 🇰🇷
Hallym University Sacred Heart Hospital, Anyang-si, Gyeonggi-do, Korea, Republic of
🇰🇷Hallym University Dongtan Sacred Heart Hospital, Hwaseong-si, Gyeonggi-do, Korea, Republic of
🇰🇷CHA Bundang Medical Center, Seongnam-si, Gyeonggi-do, Korea, Republic of
Retrospective, External Comparator Study of Lazertinib as the 2nd-Line Treatment in Patients With EGFR Mutation+ NSCLC
- Conditions
- Interventions
- First Posted Date
- 2023-05-17
- Last Posted Date
- 2023-08-22
- Lead Sponsor
- Yuhan Corporation
- Target Recruit Count
- 534
- Registration Number
- NCT05862194
An Observational, Prospective Study to Assess the Efficacy and Safety of Adalloce in Patients With RA and AS
- Conditions
- First Posted Date
- 2023-04-28
- Last Posted Date
- 2023-05-09
- Lead Sponsor
- Yuhan Corporation
- Target Recruit Count
- 1000
- Registration Number
- NCT05835518
- Locations
- 🇰🇷
Daegu Catholic University Medical Center, Daegu, Korea, Republic of
A Study to Compare the Effects of Sarpogrelate Sustained Release /Aspirin Combination Therapy Versus Aspirin on Blood Viscosity in the Patients With Peripheral Arterial Disease and Coronary Artery Disease
- Conditions
- Interventions
- First Posted Date
- 2023-02-16
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Yuhan Corporation
- Target Recruit Count
- 68
- Registration Number
- NCT05730621
- Locations
- 🇰🇷
The Catholic University of Korea Uijeongbu St. Mary's Hospital, Uijeongbu, Gyeonggi-do, Korea, Republic of
A Randomized, Active-controlled, Parallel, Open-label, Multicenter, Phase 4 Study to Compare the Efficacy and Safety of Pregabalin Sustained Release Tablet and Pregabalin Immediate Release Capsule in Type II Diabetic Patients With Peripheral Neuropathic Pain
- Conditions
- Interventions
- First Posted Date
- 2022-11-22
- Last Posted Date
- 2023-10-23
- Lead Sponsor
- Yuhan Corporation
- Target Recruit Count
- 130
- Registration Number
- NCT05624853
- Locations
- 🇰🇷
Dankook University Hospital, Cheonan, Chungcheongnam-do, Korea, Republic of
🇰🇷Kosin University Gospel Hospital, Busan, Korea, Republic of
🇰🇷Chungbuk National University Hospital, Cheongju, Chungcheongbuk-do, Korea, Republic of
A Multiple Ascending Dose, Phase 1b Study of YH35324 in Atopic Healthy Subjects or Subjects with Allergic Diseases
- Conditions
- Interventions
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Yuhan Corporation
- Target Recruit Count
- 46
- Registration Number
- NCT05564221
- Locations
- 🇰🇷
Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of
🇰🇷Nowon Eulji Medical Center, Seoul, Korea, Republic of
🇰🇷Korea University Anam Hospital, Seoul, Korea, Republic of
Clinical Trial of YH32367 in Patients with HER2 Positive Locally Advanced or Metastatic Solid Tumor
- First Posted Date
- 2022-09-01
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Yuhan Corporation
- Target Recruit Count
- 137
- Registration Number
- NCT05523947
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
🇰🇷The Catholic University of Korea, St. Mary's hospital, Seoul, Korea, Republic of
🇦🇺Southern Oncology Clinical Research Unit, Adelaide, Australia
BE Study of Two Formulations of Rivaroxaban 2.5 mg in Healthy Subjects
- Conditions
- Interventions
- First Posted Date
- 2022-06-14
- Last Posted Date
- 2022-06-16
- Lead Sponsor
- Yuhan Corporation
- Target Recruit Count
- 34
- Registration Number
- NCT05418803
- Locations
- 🇰🇷
Jeonbuk National University Hospital, Jeonju, Jeollabuk-do, Korea, Republic of